Launch of reference DNA plate for genetic testing in lung cancer
20 August 2020
On August 20, 2020, Ricoh Company., Ltd. (President and CEO Yoshinori Yamashita) and DNA Chip Research Inc. (President Ryo Matoba) announced that today they will launch “RICOH Standard DNA Series EGFR mutation Type001”, a reference DNA plate jointly developed as reference material for use in accuracy control of blood-based genetic testing for lung cancer. This product contributes to improving the accuracy of testing by making it possible to confirm the accuracy of highly sensitive genetic testing that detects the very small amounts of DNA molecules from cancer cells that are contained in blood from lung cancer patients.
EGFR Liquid has been approved as a companion diagnostic
31 July 2020
On July 31, 2020, Ryo Matoba, the president of DNA Chip Research Inc., announced that its diagnostic program, "EGFR Liquid" has been approved in Japan by the Pharmaceuticals and Medical Devices Agency (PMDA) for the detection of the epidermal growth factor receptor (EGFR) gene in DNA derived from plasma or tumor tissue. "EGFR Liquid" is a minimally invasive and a highly sensitive liquid biopsy test to detect abnormal (mutated) DNAs even in small quantities in blood for targeted therapies of lung cancer(NSCLC).
On July 10, 2019, Ryo Matoba, the president of DNA Chip Research Inc., announced that they have developed a high-sensitivity genetic test to detect a very small amount of abnormal (mutated) DNAs in blood for targeted therapies of lung cancer, and submitted its program, “EGFR Liquid” Gene Analysis Software for approval from Japanese authorities as a medical program. The genetic test can be used as companion diagnostic test in clinical practice after approval.